News & Press Releases Swedish

Scandinavian ChemoTech deltar vid den fysiska signeringen och genomför utbildning på det nyligen initierade Centre of Excellence ”CoE” i Indien

Bolagets CEO Mohan Frick närvarade vid den fysiska signeringsceremonin och därmed den officiella starten av det Centre of Excellence "CoE" som nu initieras i samarbetet på India Sweden Healthcare Innovation Centre på AIIMS Jodhpur. De första träningsbehandlingarna med TSE genomfördes även på bröst- samt huvud- & halscancer.

Read more

Scandinavian ChemoTechs dotterbolag Vetiqure AB har initierat TSE-behandlingar på häst

Vetiqure AB som framförallt koncentrerar sig på tumörspecifik elektroporation (TSE) för veterinärmedicin har nu, tillsammans med sin samarbetspartner Evidensia Helsingborg, initierat TSE-behandlingar på häst.

Read more

Styrelseledamot köper ytterligare aktier i Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) meddelar att Martin Jerndal, styrelseledamot, den 12 november 2021 köpte ytterligare 5 000 aktier för cirka 84 600 SEK över börsen. Hans totala innehav uppgår nu till 587 695 aktier i ChemoTech.

Read more

News & Press Releases English

Scandinavian ChemoTech participates in the physical signing and conducts training at the newly initiated Centre of Excellence "CoE" in India

The Company's CEO Mohan Frick attended the physical signing ceremony and thus the official start of the Centre of Excellence collaboration, which has been initiated at India Sweden Healthcare Innovation Centre at AIIMS Jodhpur. The first TSE training treatments for breast, head and neck cancer were also performed.

Read more

Scandinavian ChemoTech's subsidiary Vetiqure AB has initiated TSE treatments on horses

Vetiqure AB, which primarily concentrates on Tumour Specific Electroporation (TSE) for veterinary medicine, has now, together with its partner Evidensia Helsingborg, initiated TSE treatments on horses.

Read more

Board member buys additional shares in Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) announces that Martin Jerndal, board member, bought further 5,000 shares on the 12[th] of November 2021 for approximately SEK 84,600 over the stock exchange. His total holding now amounts to 587,695 shares in ChemoTech.

Read more

ChemoTech Videos

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.